MENU
SEPN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SEPN stock forecast, quote, news & analysis

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform... Show more

SEPN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SEPN with price predictions
Sep 11, 2026

SEPN's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for SEPN moved out of overbought territory on August 13, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 15 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SEPN as a result. In 20 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for SEPN turned negative on August 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In 5 of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.

The 10-day moving average for SEPN crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

SEPN broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 19 of 21 cases where SEPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

SEPN moved above its 50-day moving average on September 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +3.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEPN advanced for three days, in 85 of 93 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 100 of 112 cases where SEPN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.649) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (17.391) is also within normal values, averaging (427.627).

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SEPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 130.64B. VRTX holds the highest valuation in this group at 130.64B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -6%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 2,532%. INDP experienced the highest price growth at 127%, while GOSS experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 29%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
SEPN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
250 East Grand Avenue
Phone
+1 650 338-3533
Employees
130
Web
https://www.septerna.com
SEPN's RSI Indicator peaks and leaves overbought zone